Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets

About this update from Shanghai Allist Pharmaceuticals Co. Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shanghai Allist Pharmaceuticals Co. Ltd. Class A